By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Times ReportersTimes Reporters
  • Home
  • News
  • Politics
  • Business
    • Economy
  • Sports
  • Entertainment
  • About Us
  • Bookmarks
Search
  • Home
  • About Us
  • Advertise
  • Join Us
  • Terms of Use
  • Privacy Policy
© 2024 Times Reporters | All Rights Reserved.
Reading: Breakthrough as HIV prevention drug records 100% success
Share
Sign In
Notification Show More
Latest News
NOGALSS unveils e-learning platform for underserved communities
Civil Society Organisations Metro News
ACE project nears funding close, stakeholders push sustainability
Civil Society Organisations Metro News
Karmo Village Head urges peace and spiritual reflection during Sallah
Culture Metro News
CORBON, COREN sign agreement on strengthening enforcement of construction standards
Labour News
Chief Makama’s Sallah Message: A call for peace, unity, and spiritual reflection
Culture Metro News
Aa
Times ReportersTimes Reporters
Aa
  • Home
  • News
  • Politics
  • Business
  • Sports
  • Entertainment
  • About Us
Search
  • Home
  • News
  • Politics
  • Business
  • Sports
  • Entertainment
  • About Us
Have an existing account? Sign In
Follow US
  • Home
  • About Us
  • Advertise
  • Join Us
  • Terms of Use
  • Privacy Policy
© 2024 Times Reporters | All Rights Reserved.
Times Reporters > News > Health > Breakthrough as HIV prevention drug records 100% success
HealthMetroNews

Breakthrough as HIV prevention drug records 100% success

Publisher
By Publisher Published June 24, 2024
Share
5 Min Read
SHARE

A promising new HIV prevention drug called lenacapavir has shown 100 percent efficacy in a clinical trial among adolescent girls and young women in South Africa and Uganda.

The twice-yearly injection was found to be superior to daily Truvada, the current standard for pre-exposure prophylaxis (PrEP). This is according to Gilead Sciences, the developer of lenacapavir.
In a release signed by Kay Marshall, Senior Communications Advisor for AVAC, the organization welcomes the groundbreaking results of the PURPOSE 1 study which enrolled over 5,300 cisgender adolescent girls and young women ages between the age of 16 and 26 in South Africa and Uganda.

The study evaluated injectable lenacapavir for PrEP and daily oral emtricitabine/tenofovir alafenamide (F/TAF) for PrEP.

- Advertisement -
Ad image

An independent data and safety monitoring board (DSMB), at a scheduled review of the trial data, found the regimen to be safe and highly effective, with no infections seen among trial participants who received injectable lenacapavir.

Regulation
HIV prevention advocate and AVAC’s executive director, Mitchell Warren hails the lenacapavir trial results as a significant advancement. He emphasized the potential of long-acting injectables to increase adherence, improve access, and reduce strain on healthcare systems.

“We expect to see a timeline that takes into account a full analysis of PURPOSE 1 data and the coming data from PURPOSE 2 from Gilead as soon as possible, and we urge regulatory agencies to prepare to fast track regulatory review.

“We look forward to working with civil society partners, Gilead, international donors, normative agencies and national governments to ensure that this groundbreaking HIV prevention option is made available as quickly as possible and that we don’t squander this opportunity to drive down new HIV infections,” Warren said.

The Regional Stakeholder Engagement Manager for AVAC, and a member of the PURPOSE 1 Global Community Advisory Group, Nandisile Sikwana said, “We are incredibly excited about this result, especially about what it can mean for women in Africa. We applaud Gilead’s commitment to Good Participatory Practice in this and the other PURPOSE studies.

“While we wait for full data from the study, including adherence data of oral F/TAF, it is imperative that planning for rollout of lenacapavir be accelerated. We know that even with the most ambitious timeline, it will take time for lenacapavir to be rolled out”.

A companion trial, PURPOSE 2, is underway in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the US, testing twice-yearly lenacapavir for PrEP among cisgender men who have sex with men, transgender women, transgender men, and gender non-binary people. Results from PURPOSE 2 are expected by early 2025.

… additional studies
Additional studies in critical populations, including PURPOSE 3 among cisgender women in the US and PURPOSE 4 among people who use injection drugs, are also underway, and it will be imperative to understand how today’s results influence these trials.

Gilead’s plans for submission to regulatory agencies and future access, including the US Food and Drug Administration (FDA), are not yet clear. But the results reported today make this urgent.

“We also call on WHO to be prepared to quickly include lenacapavir, if approved by regulatory agencies, in HIV prevention guidelines. There is no time to waste if we are to translate these exciting clinical trial results into actual public health impact and expand the toolbox of HIV prevention choices,” he continued.

“We now know that lenacapivir for PrEP is safe and highly effective among women. Even as we await the results of the trial among other essential populations and for regulatory submission and review, there is urgent work to be done now by communities, policymakers, funders and program implementers to design and build HIV prevention programmes and prepare health systems to deliver the growing array of biomedical PrEP options, including the addition of twice-yearly injectable lenacapavir.

“The full range of PrEP products – including oral PrEP – must be made feasible choices for all people who need and want HIV prevention options,” Sikwana added.

Like this:

Like Loading...

Related

You Might Also Like

NOGALSS unveils e-learning platform for underserved communities

ACE project nears funding close, stakeholders push sustainability

Karmo Village Head urges peace and spiritual reflection during Sallah

CORBON, COREN sign agreement on strengthening enforcement of construction standards

Chief Makama’s Sallah Message: A call for peace, unity, and spiritual reflection

TAGGED: HIV, HIV AIDS, Vaccine

Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Publisher June 24, 2024
Share this Article
Facebook Twitter Whatsapp Whatsapp LinkedIn Telegram Email Copy Link Print
Share
Previous Article Nimet completes ISO Standard Internal Audit At Regional Training Centre, Oshodi
Next Article Cholera: Minister tasks principals on measures to curtail outbreak
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Stay Connected

Facebook Like
Twitter Follow
Instagram Follow
Youtube Subscribe
Telegram Follow

– Member of –

- Advertisement -
Ad imageAd image

Latest News

NOGALSS unveils e-learning platform for underserved communities
Civil Society Organisations Metro News June 6, 2025
ACE project nears funding close, stakeholders push sustainability
Civil Society Organisations Metro News June 6, 2025
Karmo Village Head urges peace and spiritual reflection during Sallah
Culture Metro News June 5, 2025
CORBON, COREN sign agreement on strengthening enforcement of construction standards
Labour News June 5, 2025

You Might also Like

Civil Society OrganisationsMetroNews

NOGALSS unveils e-learning platform for underserved communities

June 6, 2025
Civil Society OrganisationsMetroNews

ACE project nears funding close, stakeholders push sustainability

June 6, 2025
CultureMetroNews

Karmo Village Head urges peace and spiritual reflection during Sallah

June 5, 2025
LabourNews

CORBON, COREN sign agreement on strengthening enforcement of construction standards

June 5, 2025
Times ReportersTimes Reporters
Follow US

© 2024 Times Reporters | Deigned by AuspiceWeb Graphics. All Rights Reserved.

  • Home
  • About Us
  • Advertise
  • Join Us
  • Terms of Use
  • Privacy Policy
Join Us!

Subscribe to our newsletter and never miss our latest news!

Zero spam, Unsubscribe at any time.

Removed from reading list

Undo
Welcome Back!

Sign in to your account

Lost your password?
%d